Alzheimer’s disease is a progressive, irreversible brain disorder that affects memory, thinking, and language skills. Over time, people living with Alzheimer’s disease may become unable to ...

The U.S. Food and Drug Administration cleared the first blood test, which measures two key biomarkers, to aid in diagnosing Alzheimer’s disease in people exhibiting symptoms of the …

Once finalized, the guidance will provide recommendations to help drug companies developing medicines to treat patients with early stages of Alzheimer’s disease that occur before the onset …

The FDA converted Leqembi (lecanemab-irmb), indicated to treat adult patients with Alzheimer’s Disease, to traditional approval.

Aug 28, 2025 · Symptoms of dementia include the loss of memory, problem-solving, and ability to think clearly which can interfere with daily life. Alzheimer’s disease is the most common type of …

Administration and Scoring Manual Alzheimer’s Disease Assessment Scale – Cognitive (ADAS-cog) 3/20/12

Jul 2, 2024 · Alzheimer’s disease is an irreversible, progressive brain disorder affecting more than 6.5 million Americans that slowly destroys memory and thinking skills and, eventually, the …

As a result of FDA’s approval of Aduhelm, patients with Alzheimer’s disease have an important and critical new treatment to help combat this disease.

Eli Lilly and Company (Lilly) is seeking approval of donanemab for the treatment of patients with Alzheimer’s disease (AD) presenting with mild cognitive impairment or mild dementia and with ...

Alzheimer’s disease is a progressive, irreversible brain disorder that a ects memory, thinking, and language skills. Over time, people living with Alzheimer’s disease may become unable to ...